DSM-Firmenich has initiated legal action for patent infringement against a second Chinese company this month.
The company took action in China against Shandong Haineng Bioengineering Co. Ltd., alleging that certain Haineng swine compound premix containing 25-hydroxyvitamin D3 constitutes unlawful use of DSM-Firmenich’s patented technology. The petition filed with the court asks it to order that Haineng cease using DSM-Firmenich’s patented technology and pay compensation for the infringement.
“As a lead innovator in the 25-hydroxyvitamin D3 area, we hold and have been expanding a comprehensive patent portfolio throughout the value chain. From the manufacturing of crystalline 25-hydroxyvitamin D3, its formulations and its applications, the DSM-Firmenich patent portfolio protects the exhaustive scientific research and development that has gone into both our innovative technologies and business,” said Christie Chavis, head of performance solutions + Biomin at DSM-Firmenich. “We actively enforce patents against infringement to support and continue to invest in much-needed scientific innovation to bring advancements in sustainability, health and nutrition to the animal industry.”
Earlier this month, DSM-Firmenich initiated legal action for patent infringement against Zhejiang Shengda Bio-pharm Co. Ltd. – a biotin supplier – and Anhui Shengda Bio-pharm Co. Ltd. a.k.a. Anhui Shengda Bio-engineering Co. Ltd. – a biotin intermediate manufacturer. In that case, DSM-Firmenich alleged Shengda’s production of a key biotin intermediate at its Anhui site is an unlawful use of DSM-Firmenich’s patented technology. DSM-Firmenich has petitioned the court in Anhui Province, China, to order Shengda to cease using the patented technology and pay compensation for the infringement.
